Research and Markets (http://www.researchandmarkets.com/research/3vvmps/cariprazine)
has announced the addition of the "Cariprazine
(Major Depressive Disorder) - Forecast and Market Analysis to 2023"
report to their offering.
Cariprazine (RGH-188) is being developed as an adjunctive treatment to
antidepressant therapy in patients with MDD who had an inadequate
response to antidepressant therapy, and as of April 2014, two Phase III
clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest
Laboratories, NCT01838876). In addition, cariprazine is being developed
for the treatment of schizophrenia and bipolar disorder.
Overview of Major depressive disorder, including epidemiology,
etiology, symptoms, diagnosis, pathology and treatment guidelines as
well as an overview on the competitive landscape.
Detailed information on Cariprazine including product description,
safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Cariprazine for the top eight countries from 2013
Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
Etiology and Pathophysiology
Symptoms and Subtypes of Major Depressive Disorder
Quality of Life
4 Disease Management
Treatment Guidelines and Leading Prescribed Drugs
5 Competitive Assessment
6 Unmet Needs and Opportunities
More Effective Pharmacotherapies
More Favorable Side Effect Profiles
Rapid Onset of Antidepressant Effects
Personalized Treatment Approach
7 Pipeline Assessment
8 Cariprazine (RGH-188)
For more information visit http://www.researchandmarkets.com/research/3vvmps/cariprazine
Copyright Business Wire 2014